110 related articles for article (PubMed ID: 15178414)
1. The role of long-chain fatty-acid-CoA ligase 3 in vitamin D3 and androgen control of prostate cancer LNCaP cell growth.
Qiao S; Tuohimaa P
Biochem Biophys Res Commun; 2004 Jun; 319(2):358-68. PubMed ID: 15178414
[TBL] [Abstract][Full Text] [Related]
2. Expression and vitamin D3 regulation of long-chain fatty-acid-CoA ligase 3 in human prostate cancer cells.
Qiao S; Tuohimaa P
Prostaglandins Leukot Essent Fatty Acids; 2011; 84(1-2):19-23. PubMed ID: 21041072
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D3 inhibits fatty acid synthase expression by stimulating the expression of long-chain fatty-acid-CoA ligase 3 in prostate cancer cells.
Qiao S; Tuohimaa P
FEBS Lett; 2004 Nov; 577(3):451-4. PubMed ID: 15556626
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
5. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells.
Bao BY; Hu YC; Ting HJ; Lee YF
Oncogene; 2004 Apr; 23(19):3350-60. PubMed ID: 15048085
[TBL] [Abstract][Full Text] [Related]
6. Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1alpha,24-dihydroxyvitamin D2.
Bauer JA; Thompson TA; Church DR; Ariazi EA; Wilding G
Prostate; 2003 May; 55(3):159-67. PubMed ID: 12692781
[TBL] [Abstract][Full Text] [Related]
7. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
8. Stable expression of full length human androgen receptor in PC-3 prostate cancer cells enhances sensitivity to retinoic acid but not to 1alpha,25-dihydroxyvitamin D3.
Murthy S; Marcelli M; Weigel NL
Prostate; 2003 Sep; 56(4):293-304. PubMed ID: 12858358
[TBL] [Abstract][Full Text] [Related]
9. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
Zhao XY; Peehl DM; Navone NM; Feldman D
Endocrinology; 2000 Jul; 141(7):2548-56. PubMed ID: 10875257
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness.
Ting HJ; Bao BY; Reeder JE; Messing EM; Lee YF
Mol Cancer Res; 2007 Sep; 5(9):967-80. PubMed ID: 17855664
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
12. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays.
Krishnan AV; Shinghal R; Raghavachari N; Brooks JD; Peehl DM; Feldman D
Prostate; 2004 May; 59(3):243-51. PubMed ID: 15042599
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
Chiu FL; Lin JK
Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333
[TBL] [Abstract][Full Text] [Related]
14. Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells.
Hsieh CL; Cai C; Giwa A; Bivins A; Chen SY; Sabry D; Govardhan K; Shemshedini L
J Mol Endocrinol; 2008 Jul; 41(1):13-23. PubMed ID: 18469090
[TBL] [Abstract][Full Text] [Related]
15. Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells.
Khanim FL; Gommersall LM; Wood VH; Smith KL; Montalvo L; O'Neill LP; Xu Y; Peehl DM; Stewart PM; Turner BM; Campbell MJ
Oncogene; 2004 Sep; 23(40):6712-25. PubMed ID: 15300237
[TBL] [Abstract][Full Text] [Related]
16. Regulation of aromatase and 5alpha-reductase by 25-hydroxyvitamin D(3), 1alpha,25-dihydroxyvitamin D(3), dexamethasone and progesterone in prostate cancer cells.
Lou YR; Murtola T; Tuohimaa P
J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):151-7. PubMed ID: 15862960
[TBL] [Abstract][Full Text] [Related]
17. Growth inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31.
Moffatt KA; Johannes WU; Hedlund TE; Miller GJ
Cancer Res; 2001 Oct; 61(19):7122-9. PubMed ID: 11585744
[TBL] [Abstract][Full Text] [Related]
18. 1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells.
Serda RE; Bisoffi M; Thompson TA; Ji M; Omdahl JL; Sillerud LO
Prostate; 2008 May; 68(7):773-83. PubMed ID: 18247401
[TBL] [Abstract][Full Text] [Related]
19. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
20. Non-genomic effects of the androgen receptor and vitamin D agonist are involved in suppressing invasive phenotype of prostate cancer cells.
Bonaccorsi L; Marchiani S; Ferruzzi P; Muratori M; Crescioli C; Forti G; Maggi M; Baldi E
Steroids; 2006 Apr; 71(4):304-9. PubMed ID: 16289173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
